A novel carcinoembryonic antigen t cell bispecific antibody (cea tcb) for the treatment of solid tumors by Bacac, M, Fauti, T, Sam, J, Colombetti, S, Weinzierl, T, Ouaret, D, Bodmer, W, Lehmann, S, Hofer, T, Hosse, R, Moessner, E, Ast, O, Bruenker, P, Grau-Richards, S, Schaller, T, Seidl, A, Gerdes, C, Perro, M, Nicolini, V, Steinhoff, N, Dudal, S, Neumann, S, von Hirschheydt, T, Jaeger, C, Saro, J, Karanikas, V, Klein, C, Umana, P

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma by Grandclément, C, Estoppey, C, Dheilly, E, Panagopoulou, M, Monney, T, Dreyfus, C, Loyau, J, Labanca, V, Drake, A, De Angelis, S, Rubod, A, Frei, J, Caro, LN, Blein, S, Martini, E, Chimen, M, Matthes, T, Kaya, Z, Edwards, CM, Edwards, JR, Menoret, E, Kervoelen, C, Pellat-Deceunynck, C, Moreau, P, Mbow, ML, Srivastava, A, Dyson, MR, Zhukovsky, EA, Perro, M, Sammicheli, S

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma by Pouleau, B, Estoppey, C, Suere, P, Nallet, E, Laurendon, A, Monney, T, Pais Ferreira, D, Drake, A, Carretero-Iglesia, L, Macoin, J, Berret, J, Pihlgren, M, Doucey, M-A, Gudi, GS, Menon, V, Udupa, V, Maiti, A, Borthakur, G, Srivastava, A, Blein, S, Mbow, ML, Matthes, T, Kaya, Z, Edwards, C, Edwards, JR, Menoret, E, Kervoëlen, C, Pellat-Deceunynck, C, Moreau, P, Zhukovsky, E, Perro, M, Chimen, M